Insider Buying: Biodesix, Inc. (NASDAQ:BDSX) Director Acquires $56,000.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck acquired 40,000 shares of Biodesix stock in a transaction that occurred on Tuesday, November 5th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $56,000.00. Following the completion of the purchase, the director now directly owns 2,606,879 shares of the company’s stock, valued at $3,649,630.60. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Biodesix Price Performance

Shares of NASDAQ:BDSX opened at $1.37 on Friday. The stock has a market cap of $199.29 million, a price-to-earnings ratio of -3.41 and a beta of 1.22. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.28. Biodesix, Inc. has a 12 month low of $1.15 and a 12 month high of $2.21. The stock’s 50 day moving average price is $1.68 and its 200 day moving average price is $1.61.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Friday, November 1st. The company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $18.15 million during the quarter, compared to analyst estimates of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. During the same quarter last year, the firm posted ($0.12) EPS. Equities research analysts anticipate that Biodesix, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biodesix

Several hedge funds have recently modified their holdings of the stock. Essex Investment Management Co. LLC boosted its stake in Biodesix by 1.4% in the 1st quarter. Essex Investment Management Co. LLC now owns 925,614 shares of the company’s stock worth $1,324,000 after purchasing an additional 12,669 shares during the period. Opaleye Management Inc. boosted its position in shares of Biodesix by 7.7% in the first quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after buying an additional 38,157 shares during the period. CVI Holdings LLC acquired a new stake in shares of Biodesix in the second quarter worth $59,000. Landscape Capital Management L.L.C. acquired a new position in Biodesix during the third quarter valued at $262,000. Finally, Perkins Capital Management Inc. raised its position in Biodesix by 74.7% during the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after buying an additional 310,000 shares during the period. 20.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on BDSX shares. Scotiabank assumed coverage on shares of Biodesix in a report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 target price on the stock. Craig Hallum assumed coverage on Biodesix in a report on Friday, July 26th. They set a “buy” rating and a $3.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $3.06.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.